Tenaya Therapeutics gets fast track designation for gene therapy TN-201

Image: This therapy is being developed to treat Myosin Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM). Credit: Pexels from Pixabay.



  • Tenaya Therapeutics